Menlo Park, CA, United States of America

Matthew Ian Hoopes

This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Adicet Therapeutics, Inc.. Active years: 2025.

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 8.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Matthew Ian Hoopes: Innovator in T-Cell Expansion Technologies

Introduction

Matthew Ian Hoopes is a notable inventor based in Menlo Park, California. He has made significant contributions to the field of immunology, particularly in the expansion of T-cell populations. His innovative work has the potential to impact therapeutic approaches for various medical conditions.

Latest Patents

Matthew Ian Hoopes holds a patent titled "Methods for selective expansion of delta-3 gamma delta T-cell populations and compositions thereof." This patent focuses on agents that bind to an epitope specific to a δ3 γδ TCR. The agents can include antibodies or fragments thereof. The patent also describes methods for using these agents to expand or selectively expand δ3 γδ T cells, which can be utilized for treating subjects in need.

Career Highlights

Matthew is currently associated with Adicet Therapeutics, Inc., where he continues to advance his research and development efforts. His work at the company emphasizes innovative solutions in the field of immunotherapy.

Collaborations

Matthew has collaborated with notable professionals in his field, including Aya Jakobovits and Daulet Kadyl Satpayev. These collaborations enhance the research and development efforts at Adicet Therapeutics, Inc.

Conclusion

Matthew Ian Hoopes is a distinguished inventor whose work in T-cell expansion technologies holds promise for future medical treatments. His contributions to the field of immunology are noteworthy and reflect his commitment to advancing healthcare solutions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…